Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) and Star Equity (NASDAQ:STRR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
Institutional and Insider Ownership
98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Star Equity shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 28.8% of Star Equity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Aclaris Therapeutics and Star Equity”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclaris Therapeutics | $32.02 million | 2.65 | -$88.48 million | ($1.09) | -1.09 |
| Star Equity | $47.15 million | 0.27 | $25.13 million | $6.50 | 0.62 |
Analyst Ratings
This is a breakdown of current recommendations for Aclaris Therapeutics and Star Equity, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclaris Therapeutics | 0 | 6 | 0 | 0 | 2.00 |
| Star Equity | 0 | 0 | 0 | 0 | N/A |
Aclaris Therapeutics presently has a consensus price target of $9.00, suggesting a potential upside of 656.30%. Given Aclaris Therapeutics’ higher possible upside, research analysts plainly believe Aclaris Therapeutics is more favorable than Star Equity.
Risk and Volatility
Aclaris Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500.
Profitability
This table compares Aclaris Therapeutics and Star Equity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclaris Therapeutics | -183.28% | -53.18% | -41.74% |
| Star Equity | -14.65% | -5.74% | -3.34% |
Summary
Star Equity beats Aclaris Therapeutics on 8 of the 12 factors compared between the two stocks.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
About Star Equity
Star Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
